264 related articles for article (PubMed ID: 23724141)
1. MSH3 mismatch repair protein regulates sensitivity to cytotoxic drugs and a histone deacetylase inhibitor in human colon carcinoma cells.
Park JM; Huang S; Tougeron D; Sinicrope FA
PLoS One; 2013; 8(5):e65369. PubMed ID: 23724141
[TBL] [Abstract][Full Text] [Related]
2. MSH3 mediates sensitization of colorectal cancer cells to cisplatin, oxaliplatin, and a poly(ADP-ribose) polymerase inhibitor.
Takahashi M; Koi M; Balaguer F; Boland CR; Goel A
J Biol Chem; 2011 Apr; 286(14):12157-65. PubMed ID: 21285347
[TBL] [Abstract][Full Text] [Related]
3. MSH3 expression does not influence the sensitivity of colon cancer HCT116 cell line to oxaliplatin and poly(ADP-ribose) polymerase (PARP) inhibitor as monotherapy or in combination.
Tentori L; Muzi A; Dorio AS; Dolci S; Campolo F; Vernole P; Lacal PM; Praz F; Graziani G
Cancer Chemother Pharmacol; 2013 Jul; 72(1):117-25. PubMed ID: 23636450
[TBL] [Abstract][Full Text] [Related]
4. Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses.
Meyers M; Wagner MW; Hwang HS; Kinsella TJ; Boothman DA
Cancer Res; 2001 Jul; 61(13):5193-201. PubMed ID: 11431359
[TBL] [Abstract][Full Text] [Related]
5. Interdependence of DNA mismatch repair proteins MLH1 and MSH2 in apoptosis in human colorectal carcinoma cell lines.
Hassen S; Ali AA; Kilaparty SP; Al-Anbaky QA; Majeed W; Boman BM; Fields JZ; Ali N
Mol Cell Biochem; 2016 Jan; 412(1-2):297-305. PubMed ID: 26728996
[TBL] [Abstract][Full Text] [Related]
6. Different effects of epigenetic modifiers on the cytotoxicity induced by 5-fluorouracil, irinotecan or oxaliplatin in colon cancer cells.
Ikehata M; Ogawa M; Yamada Y; Tanaka S; Ueda K; Iwakawa S
Biol Pharm Bull; 2014; 37(1):67-73. PubMed ID: 24172061
[TBL] [Abstract][Full Text] [Related]
7. Loss of MLH1 sensitizes colon cancer cells to DNA-PKcs inhibitor KU60648.
Hinrichsen I; Ackermann A; Düding T; Graband A; Filmann N; Plotz G; Zeuzem S; Brieger A
Mol Carcinog; 2017 Jul; 56(7):1816-1824. PubMed ID: 28224663
[TBL] [Abstract][Full Text] [Related]
8. Influence of MLH1 on colon cancer sensitivity to poly(ADP-ribose) polymerase inhibitor combined with irinotecan.
Tentori L; Leonetti C; Muzi A; Dorio AS; Porru M; Dolci S; Campolo F; Vernole P; Lacal PM; Praz F; Graziani G
Int J Oncol; 2013 Jul; 43(1):210-8. PubMed ID: 23653048
[TBL] [Abstract][Full Text] [Related]
9. Olaparib-mediated enhancement of 5-fluorouracil cytotoxicity in mismatch repair deficient colorectal cancer cells.
de Castro E Gloria H; Jesuíno Nogueira L; Bencke Grudzinski P; da Costa Ghignatti PV; Guecheva TN; Motta Leguisamo N; Saffi J
BMC Cancer; 2021 Apr; 21(1):448. PubMed ID: 33888065
[TBL] [Abstract][Full Text] [Related]
10. Effects of the HDAC inhibitor CG2 in combination with irinotecan, 5-fluorouracil, or oxaliplatin on HCT116 colon cancer cells and xenografts.
Na YS; Kim SM; Jung KA; Yang SJ; Hong YS; Ryu MH; Ro S; Cho DH; Kim JC; Jin DH; Lee JS; Kim TW
Oncol Rep; 2010 Dec; 24(6):1509-14. PubMed ID: 21042746
[TBL] [Abstract][Full Text] [Related]
11. Differential cellular responses to prolonged LDR-IR in MLH1-proficient and MLH1-deficient colorectal cancer HCT116 cells.
Yan T; Seo Y; Kinsella TJ
Clin Cancer Res; 2009 Nov; 15(22):6912-20. PubMed ID: 19861440
[TBL] [Abstract][Full Text] [Related]
12. Rapid DNA double-strand breaks resulting from processing of Cr-DNA cross-links by both MutS dimers.
Reynolds MF; Peterson-Roth EC; Bespalov IA; Johnston T; Gurel VM; Menard HL; Zhitkovich A
Cancer Res; 2009 Feb; 69(3):1071-9. PubMed ID: 19141647
[TBL] [Abstract][Full Text] [Related]
13. Human colon cancer cells surviving high doses of cisplatin or oxaliplatin in vitro are not defective in DNA mismatch repair proteins.
Sergent C; Franco N; Chapusot C; Lizard-Nacol S; Isambert N; Correia M; Chauffert B
Cancer Chemother Pharmacol; 2002 Jun; 49(6):445-52. PubMed ID: 12107548
[TBL] [Abstract][Full Text] [Related]
14. The use of Olaparib (AZD2281) potentiates SN-38 cytotoxicity in colon cancer cells by indirect inhibition of Rad51-mediated repair of DNA double-strand breaks.
Tahara M; Inoue T; Sato F; Miyakura Y; Horie H; Yasuda Y; Fujii H; Kotake K; Sugano K
Mol Cancer Ther; 2014 May; 13(5):1170-80. PubMed ID: 24577941
[TBL] [Abstract][Full Text] [Related]
15. MLH1-deficient tumor cells are resistant to lipoplatin, but retain sensitivity to lipoxal.
Fedier A; Poyet C; Perucchini D; Boulikas T; Fink D
Anticancer Drugs; 2006 Mar; 17(3):315-23. PubMed ID: 16520660
[TBL] [Abstract][Full Text] [Related]
16. Association between mismatch repair gene and irinotecan-based chemotherapy in metastatic colon cancer.
Ma J; Zhang Y; Shen H; Kapesa L; Liu W; Zeng M; Zeng S
Tumour Biol; 2015 Dec; 36(12):9599-609. PubMed ID: 26142736
[TBL] [Abstract][Full Text] [Related]
17. Presence of MLH1 protein aggravates the potential of the HSP90 inhibitor radicicol to sensitize tumor cells to cisplatin.
Fedier A; Stuedli A; Fink D
Int J Oncol; 2005 Dec; 27(6):1697-705. PubMed ID: 16273226
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of the DSB repair protein RAD51 potentiates the cytotoxic efficacy of doxorubicin via promoting apoptosis-related death pathways.
Schürmann L; Schumacher L; Roquette K; Brozovic A; Fritz G
Cancer Lett; 2021 Nov; 520():361-373. PubMed ID: 34389435
[TBL] [Abstract][Full Text] [Related]
19. Saffron and Its Major Ingredients' Effect on Colon Cancer Cells with Mismatch Repair Deficiency and Microsatellite Instability.
Amin A; Farrukh A; Murali C; Soleimani A; Praz F; Graziani G; Brim H; Ashktorab H
Molecules; 2021 Jun; 26(13):. PubMed ID: 34202689
[TBL] [Abstract][Full Text] [Related]
20. Synergy between histone deacetylase inhibitors and DNA-damaging agents is mediated by histone deacetylase 2 in colorectal cancer.
Alzoubi S; Brody L; Rahman S; Mahul-Mellier AL; Mercado N; Ito K; El-Bahrawy M; Silver A; Boobis A; Bell JD; Hajji N
Oncotarget; 2016 Jul; 7(28):44505-44521. PubMed ID: 27283986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
